Immunogenicity and safety of severe acute respiratory syndrome coronavirus 2 vaccination among outpatients receiving immunosuppressive therapy: A monocentric observational study in Japa
Not Applicable
- Conditions
- patients who were receiving immunosuppressive therapy
- Registration Number
- JPRN-UMIN000044499
- Lead Sponsor
- Shonan Fujsiawa Tokushukai Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
age less than 15 years, infected with SARS-CoV-2 and quarantined, already vaccinated, not willing to be vaccinated on their own or on the recommendation of their physician, undergoing treatment for cancer, and not providing informed consent.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Antibody titer of anti-spike protein IgG before first vaccination, 3 weeks, 5 weeks, 90 days, and 180 days after vaccination
- Secondary Outcome Measures
Name Time Method